| Clinical data | |
|---|---|
| Other names | ZK-136295; Cycloestriol; 14α,17α-Ethanoestriol; 14α,17α-Ethanoestra-1,3,5(10)-triene-3,16α,17β-triol; 14,21-Cyclo-19-norpregna-1,3,5(10)-triene-3,16α,17α-triol |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen |
| Pharmacokinetic data | |
| Bioavailability | 40%[1] |
| Eliminationhalf-life | 12.3 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H26O3 |
| Molar mass | 314.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cyclotriol (developmental code nameZK-136295; also known as14α,17α-ethanoestriol) is asyntheticestrogen which was studied in the 1990s and was never marketed.[2][1][3][4] It is aderivative ofestriol with abridge between the C14α and C17α positions.[2][1][3][5] The drug has 40% of therelative binding affinity of estradiol for the humanERα.[2] It showed anabsolute bioavailability of 40% with highinterindividual variability and anelimination half-life of 12.3 hours inpharmacokinetic studies in women.[1]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |